Loading...

Clarity Pharmaceuticals Ltd

CU6.AXASX
Healthcare
Biotechnology
A$4.46
A$0.09(2.06%)

Clarity Pharmaceuticals Ltd (CU6.AX) Company Profile & Overview

Explore Clarity Pharmaceuticals Ltd’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Clarity Pharmaceuticals Ltd (CU6.AX) Company Profile & Overview

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

SectorHealthcare
IndustryBiotechnology
CEOMichelle Parker

Contact Information

61 2 9209 4037
National Innovation Centre, Sydney, NSW, 2015

Company Facts

50 Employees
IPO DateAug 25, 2021
CountryAU
Actively Trading

Frequently Asked Questions

;